Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Pharma Giants Concered About China’s New Anti-Monopoly Law

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Leading executives at multinational firms operating in China, including some pharmaceutical giants, are concerned that the country's new anti-monopoly law could be used to counter strong market positions or to forced licensing of innovative products to competitors
Advertisement

Related Content

China Orders Pfizer And Wyeth To Divest Certain Operations As Condition To Merger Approval
China Orders Pfizer And Wyeth To Divest Certain Operations As Condition To Merger Approval
As Merger With Wyeth Hangs In The Balance Of Beijing's Hands, Pfizer CEO Tours China To Launch Scholarly Partnerships
China’s New Legal Power To Limit Or Block Mergers Could Signal Challenges For Global Pharmaceutical Alliances
China's New Legal Power To Limit Or Block Mergers Could Signal Challenges Ahead For Global Pharmaceutical Alliances
68 Billon Dollar Question: Could China's Government Block Worldwide Merger Of Wyeth And Pfizer?
2008 In Review: China’s Major Legal & Regulatory Changes For Healthcare Sector
China’s Government Might Phase Out Ad Hoc Price Controls On Drugs
Magnitude 7.9 Quake Cut into Simcere Pharmaceutical’s First-half Earnings; Company “Very Close” To First Round Of Acquistions
Insider Analysis From Sidley Austin LLP: Getting Ready For China’s Anti-Monopoly Law
Advertisement
UsernamePublicRestriction

Register

SC069123

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel